Hidradenitis suppurativa in a patient with Warkany syndrome: Sustainability of adalimumab treatment

Dermatol Ther. 2020 Jan;33(1):e13160. doi: 10.1111/dth.13160. Epub 2019 Nov 21.

Abstract

Mental retardation is a potential limitation to self-administration of innovative biologic treatment, which is otherwise very effective for devastating chronic inflammatory conditions, such as hidradenitis suppurativa (HS). We report our successful experience with a 34-year-old woman, who was genetically affected by Warkany syndrome, which causes intellectual disability. This patient was unable to maintain long-term antibiotic regimen and was disappointed by the limited results in her 12 years' history of painful draining fistulae and abscesses; however, she enthusiastically adhered to adalimumab 40 mg/once weekly treatment. After 52 weeks, treatment compliance is excellent, the patient is satisfied with the HS improvements, and no adverse effects have been reported.

Keywords: Warkany syndrome; adalimumab; hidradenitis suppurativa; mental retardation.

Publication types

  • Case Reports

MeSH terms

  • Adalimumab / administration & dosage*
  • Adult
  • Anti-Inflammatory Agents / administration & dosage*
  • Chromosomes, Human, Pair 8
  • Female
  • Hidradenitis Suppurativa / drug therapy*
  • Humans
  • Intellectual Disability / complications
  • Medication Adherence
  • Patient Satisfaction
  • Syndrome
  • Treatment Outcome
  • Trisomy / physiopathology

Substances

  • Anti-Inflammatory Agents
  • Adalimumab

Supplementary concepts

  • Chromosome 8, trisomy